Oral Cancer News

Neck response to chemoradiotherapy

Source: Arch Otolaryngol Head Neck Surg. 2009;135(11):1133-1136 Author: Alexander Langerman, MD et al. Complete Radiographic Response Correlates With Pathologic Complete Response in Locoregionally Advanced Head and Neck Cancer Objective: The role of neck dissection following chemoradiotherapy (CRT) for locoregionally advanced head and neck cancer is an area of active debate. Patients who have a complete [...]

Continue reading...

Oncolytics’ Phase III borrows adaptive design in SPA trial

Source: www.bioworld.com Author: Catherine Hollingsworth Oncolytics Biotech Inc. reached agreement with the FDA on the design of a Phase III trial of Reolysin in head and neck cancer, marking the first such agreement for an intravenously administered oncolytic virus. The Phase III trial will be conducted in two stages and will cost an estimated $15 [...]

Continue reading...

Oncolytics Biotech(R) Inc. collaborators present positive head and neck results in phase I/II combination

Source: pr-canada.net Author: press release Oncolytics Biotech Inc. announced that interim clinical results from its Phase I/II U.K. trial of Reolysin(R) combined with paclitaxel/carboplatin for patients with advanced cancers were presented at the Fifth International Meeting on Replicating Oncolytic Virus Therapeutics. The meeting is being held in Banff, Alberta from March 18th to 22nd, 2009. [...]

Continue reading...

New platinum-phosphate compounds kill ovarian vancer cells, other cancer cells

Source: www.sciencedaily.com Author: staff A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published in the journal Proceedings of the National Academy of Sciences. The compounds could be less harmful than current cancer treatments on [...]

Continue reading...

Virus accomplice helps drugs fight cancer

Source: www.newscientist.com Author: Andy Coghlan A virus that harmlessly infects most people at some time in their lives appears to help anti-cancer drugs destroy tumours, or at least keep them in check. Known as a reovirus, it destroys tumour cells because they lack the cellular machinery that keeps the virus in check in healthy cells. [...]

Continue reading...

Oncolytics reports positive results from phase I/II cancer studies

Source: www.pharmaceutical-business-review.com Author: staff Oncolytics Biotech has announced positive interim results in its Phase I and Phase II UK combination Reolysin and paclitaxel/carboplatin clinical trials for patients with advanced cancers. Four of the responding patients continue on study, while a fifth patient is too early to evaluate for response, the company said. These results appear [...]

Continue reading...

Oncolytics Biotech Inc. starts patient enrolment in U.S. phase 2 clinical trial investigating Reolysin(R) in combination with paclitaxel and carboplatin

Source: www.marketwatch.com Author: press release Oncolytics Biotech Inc. announced today that that it has started patient enrollment in a Phase 2 clinical trial using intravenous administration of Reolysin(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The Principal Investigator is Dr. Monica Mita of the Cancer Therapy & Research [...]

Continue reading...

Platinum-based chemotherapy plus cetuximab in head and neck cancer

Source: New England Journal of Medicine, Volume 359:1116-1127, September 11, 2008, Number 11 Authors: Jan B. Vermorken, M.D., Ph.D. et al. Background: Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-cell carcinoma of the head and neck. We investigated the efficacy of cetuximab plus platinum-based chemotherapy as first-line treatment in patients with recurrent or metastatic [...]

Continue reading...